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Lipopolysaccharide (LPS) is a major outer cell wall component of Gram-negative 
bacteria, including Escherichia coli and Salmonella enterica, which have important health and 
economic consequences in animal agriculture. LPS is a recognized endotoxin that stimulates toll-
like receptors, which are present on cells that contribute to inflammatory responses and, via 
downstream signaling pathways, results in the release of pro- and anti-inflammatory mediators to 
assist with pathogen clearance and tissue repair.  
During weaning, piglets are subjected to numerous psychological and environmental 
stressors including mixing, lower ambient temperature and change in diet. Due to the piglets’ 
immature digestive and immune system, weaning is associated with growth plateaus, increased 
incidence of diarrhea, increased bacterial translocation and endotoxin load, and increased 
mortality. Increased concentrations of LPS in circulation perpetuate post-wean syndrome and 
drive further gastrointestinal tract (GIT) morphological and digestive perturbations. Weaning is 
also characterized by reductions in intestinal alkaline phosphatase (IAP), which has biological 
roles including detoxifying LPS in the intestinal lumen and maintaining an alkalotic pH to 
modulate gut microbiota. IAP is a homodimeric enzyme that catalyzes the release of an inorganic 
phosphate from the lipid A moiety of LPS, resulting in the considerably less immunostimulatory 
product, monophosphoryl lipid A (MPLA).  
Based on IAP’s ability to reduce the inflammatory effects of LPS in the GIT and the 
difficulty in creating a viable commercial product from a mammalian-derived enzyme; a microbe 
was engineered to produce an alkaline phosphatase (MAP). However, the ability of MAP to 
detoxify LPS in vitro and in vivo has not been investigated. In chapter 2, to test the hypothesis 
that MAP would detoxify LPS similarly to IAP, RAW264 macrophages and primary porcine 
alveolar macrophages were treated with vehicle, IAP, MAP, E. coli or S. enterica LPS, LPS that 
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had been pre-incubated with MAP (MPLA), or LPS that had been pre-incubated with IAP 
(iMPLA). In support of the hypothesis, cells treated with MPLA had significantly lower TNFα, 
IL-6, IL-1β, and IL-10 gene expression as compared to cells treated with LPS alone. 
Furthermore, novel findings indicate an increased efficacy for MAP to detoxify LPS as 
compared to IAP. MPLA treated cells had significantly lower levels of pro- and anti-
inflammatory cytokine production as compared to iMPLA-treated cells. We then determined the 
serum cytokine profiles of piglets 2 days post-wean after being challenged with saline, MPLA, or 
LPS for four hours. Piglets i.p. injected with MPLA were more active and ate more over the time 
period than LPS injected piglets. Furthermore, MPLA piglets had altered serum cytokine profiles 
indicating an ameliorated immune response to the challenge.  
In chapter 3 we investigated the effects of exogenous MAP supplementation on post-
wean syndrome in piglets on a standard phase 2 diet. We found that adding 4,000 IU/kg body 
weight to a phase 2 diet for two weeks post-weaning resulted in a higher average daily gain and 
body weight. MAP-fed piglets had increased villus height and decreased crypt depth, and an 
increased villus height to crypt depth ratio in the duodenum, jejunum, and ileum. Furthermore, 
MAP-fed piglets were protected against weaning-induced downregulation of tight junction 
protein ZO-1 and inflammation-induced increases in claudin-1. IAP is known to be 
downregulated post-weaning due to increased inflammatory mediators which inhibit gene 
expression. Therefore, we sought to determine the effects of exogenous MAP supplementation 
on endogenous IAP gene expression and found that dietary MAP-supplementation significantly 
increased IAP gene expression in the duodenum, jejunum, and ileum. Furthermore, alkaline 
phosphatase activity was significantly higher in the digesta and mucosa of the duodenum, 
jejunum, and ileum of weaned pigs eating a MAP-supplemented diet. 
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This is the first study, to our knowledge, to characterize the effects of exogenous alkaline 
phosphatase supplementation on post wean syndrome in piglets. Our data indicates that MAP 
may serve as a potential dietary additive to mitigate the effects of LPS- and weaning-induced 
inflammation on innate immune cell cytokine production, GIT permeability and morphology, 
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CHAPTER 1: LITERATURE REVIEW 
Post-Wean Syndrome 
In the modern swine industry, weaning is the most challenging and stressful point in the pig’s 
life due to major nutritional, psychological, and environmental stressors. The piglet is removed 
from sow’s milk and transferred to a novel environment with different ambient temperature and 
mixed with other piglets. The post-weaning phase is often accompanied by reduced growth 
performance, reduced feed intake, and increased incidence of diarrhea and bacterial 
translocation1,2. Commercial pigs are typically weaned between twenty-one and twenty-eight 
days of age and have immature digestive and immune systems, which contribute to the pathology 
of the post-weaning syndrome.  
The immature digestive system of the piglet and decreased feed intake due to post-weaning 
syndrome are associated with significant gastrointestinal tract (GIT) disturbances characterized 
by changes in intestinal morphology that increase susceptibility to diarrhea and growth 
plateaus3,4. The epithelial lining of the small intestine is covered in villi, small finger-like 
projections, to increase surface area for digestion and absorption5. Optimal function of the small 
intestine favors long villi. At the base of the villi, the mucosal surface of the small intestine has 
tubular glands that open into the intestinal lumen known as crypts. Crypts contain stem cells 
required for replacement of the epithelial cell lining6. There is a brief period of villous atrophy 
and crypt hyperplasia following weaning that leads to impaired gut absorptive capacity and 
decreased digestive and brush-border enzymatic activity3,7,8. The large intestine is composed of 
the caecum, colon, and rectum, and the main functions are fluid and electrolyte absorption and 
the supply of a physical barrier against microbial translocation. Weaning induces a decreased 
crypt density in the caecum of the large intestine and a transient reduction in the absorptive 
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capacity of the colon4,9. Stress from a novel environment and littermates also contribute to 
decreased villus height and increased crypt depth in the weaned piglet. Glucagon, a stress-
associated catabolic hormone that mobilizes stored energy, had an elevated blood concentration 
in piglets’ day two to five post-wean and may contribute to intestinal changes10. Other stress 
hormones, cortisol, and corticotrophin-releasing factor, also had elevated blood plasma 
concentration after weaning11,12. 
Post-weaning diarrhea (PWD) is part of the post-weaning syndrome and represents one of the 
most significant economic wastes for the pig industry. PWD is characterized by frequent 
discharge of watery feces during the first two weeks post-weaning. One of the essential functions 
of the small intestine is nutrient digestion and absorption. This includes secretion of fluids and 
electrolytes from crypt cells and nutrient absorption via enterocytes from the intestinal brush-
border13,14. Weaning reduces the small intestines’ capacity for net absorption of fluid and 
electrolytes and leads to malabsorption of nutrients15,16. Following weaning, a net secretory 
condition can occur when the fluid and electrolyte influx into the GIT lumen exceeds the efflux 
into the blood, and this contributes to the pathology of PWD13,14. PWD is also associated with 
increased fecal shedding of a significant number of enterotoxigenic E.coli serotypes that 
proliferate in the small intestine17,18.  
Another significant role of the small intestine is to act as a barrier against antigens and 
pathogens. The gastrointestinal tract is lined with a single layer of epithelial cells that form a 
selective barrier and act as the first line of defense against potentially harmful compounds and 
microorganisms in the intestinal lumen. Intestinal barrier dysfunction is characterized by 
increased intestinal permeability, or “leaky gut,” which allows harmful immunogenic agents to 
cross the epithelium and gain access to protected tissues and systemic circulation. This breach of 
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the epithelial lining and subsequent translocation of luminal contents leads to increased 
inflammation, malabsorption, diarrhea, and potential enteric disease 4,19,20. The various 
environmental and psychological stressors on the weanling piglet contribute to the deterioration 
of the small intestinal barrier function, most likely through the release of stress mediators, 
including the aforementioned corticotrophin-releasing factor and adrenal glucocorticoids21–23. 
Morphological changes may impair intestinal barrier function and lead to increased gut 
permeability, which results in increased bacterial translocation and inflammatory response. 
Enterocytes are joined together by tight junctions that consist of proteins which function to 
connect the cytoskeletons of adjacent enterocytes24. Tight junctions are mainly constructed from 
the transmembrane protein complexes occludins and claudins, and the cytosolic protein zonula 
occludens. Alterations in tight junction proteins are biomarkers of increased intestinal 
permeability. Increased translocation of enteric pathogens, including endotoxins from Gram-
negative bacteria, disrupt these proteins and increase intestinal permeability25. The immature 
nature of the weanling piglets immune and digestive systems contributes to the duration and 
severity of GIT dysfunction.  
Impaired barrier function led to increased pathogenic bacterial load and decreased immune 
competence by decreasing cell numbers or increasing immunosuppressive mechanisms26. 
Increased bacterial load could lead to excessive immune responses that are deleterious to the 
host, and an increase in immunosuppressive mechanisms to protect against serious damage from 
the aberrant immune response. However, immunosuppression can slow pathogen clearance and 
facilitate disease states. Nursery piglets are immuno-deficient and rely on sow’s milk for growth, 
survival, and immunity. Immunoglobulin A (IgA) is an antibody that plays an essential role in 
the immune function of mucous membranes and removal of IgA and other bioactive compounds 
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derived from sow milk contribute to the weaned piglets susceptibility to disease27–29. The 
immaturity of the intestinal immune system reduces the ability of the weaned pig to mount an 
appropriate immune response to pathogens and its ability to tolerate dietary antigens29,30. 
 
LPS, TLR4, and Immune Signaling Pathways 
The immune system is divided into the innate and adaptive immune systems. The innate 
immune system is a generalized but swift response to pathogens and consists of skin, mucous 
membranes, and defense leukocytes. The innate immune system also includes antigen presenting 
cells (APC), such as macrophages and dendritic cells, that ingest antigens and pathogens, digest 
them, and display part of the ingested material on their cell surface in the context of a major 
histocompatibility complex (MHC). The MHC is a group of genes that code for cell surface 
proteins that allow the immune system to recognize self versus nonself peptides and 
appropriately bind the correct effector immune cells. 
The adaptive immune system takes over if the innate response is unsuccessful, and the slower 
system is highly specialized. The adaptive immune system can remember specific antigens and 
combat them more efficiently and effectively during future encounters. It is made up of B and T 
lymphocytes and antibodies. When gut integrity has been compromised from various stressors, 
the goal of the innate response is to rapidly initiate effector functions to prevent extensive 
inflammation and sepsis31. The innate immune system plays a more significant role than the first 
line of defense by telling antigen presenting cells to activate and differentiate T cells towards the 
appropriate effector phenotype. T cells are responsible for the cell-mediated response of adaptive 
immunity. The type of T cell that the progenitor will polarize into is dependent upon the pattern 
of cytokine secretion from the APC. There are two classes of the major histocompatibility 
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complex; MHC I presents endogenous antigens to cytotoxic T cells (CD8+), and MHC II 
presents exogenous antigens to helper T cells (CD4+). CD8+ T cells do not continue to 
differentiate and are destined to be cytotoxic, but CD4+ T cells have five main types (TH1, TH2, 
TH17, TFH and Treg) that promote distinct responses to different types of infections. 
TH1 cells control intracellular bacteria that infect immune cells by inducing the infected 
immune cell to self-destruct. TH2 cells specialize in promoting responses to parasitic infections 
while TH17 T cells secrete specific cytokines to recruit neutrophils for clearance of extracellular 
pathogens. TFH T cells are the most recently discovered subset of CD4+ cells and have been 
implicated in signaling to B cells. TFH cells are critical for protective immune responses and are 
necessary for the development of most high affinity antibodies and memory B cells. Finally, Treg 
or regulatory T cells are responsible for maintaining self-tolerance and suppressing TH cells 
when their activities become detrimental. When activated, TH1 and cytotoxic T cells release 
cytokines to help regulate the immune response and activate other cells. Interferon-γ is one such 
cytokine released and is an activator of macrophages and an inducer of MHC II expression. B 
cells provide the humoral immune response and develop in the bone marrow. They are 
characterized by cell membrane antigen receptors made from antibody molecules. Following 
maturation, the naïve B cells migrate to secondary lymphoid organs to interact with other 
components of the immune system. Antigen binding and co-stimulation from helper T cells 
activate B cells to proliferate and differentiate in memory B cells or plasma B cells that secrete 
antibodies. Memory cells form after the initial infection and are required for a more robust 
immune response following secondary infection. Effector B cells secrete antibodies with the 
same specialized antigen binding site as their plasma membrane-bound form and are used by the 
immune system to identify foreign objects. There are five classes of antibodies (IgA, IgD, IgE, 
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IgG, and IgM), and they work directly or indirectly on pathogens. Directly, antibodies work 
through agglutination, precipitation, neutralization, or direct lysis of pathogens. Indirectly, they 
activate the complement system, which activates macrophages through opsonization, works as a 
chemoattractant for other immune cells, and contributes to the lysis, agglutination, and 
neutralization of pathogens and antigens. Antibody function provides the groundwork for 
vaccine development. 
The immune systems have evolved to recognize specific patterns, and the innate immune 
response is initiated when homeostatic functions are perturbed and surveilling immune cells 
recognize these patterns. Danger associated molecular patterns (DAMP) and pathogen associated 
molecular patterns (PAMP) are two such patterns that are recognized. DAMP are endogenous 
cell-derived molecules in response to tissue damage from stress such as necrosis, trauma, or 
cancer. PAMP are present in a diverse amount of microorganisms and are necessary for the 
organism to function, but are absent in the host to promote immunity32,33. PAMP are typically 
microbial nucleic acids, lipoproteins, surface glycoproteins, or membrane components. PAMP 
and DAMP bind to specific receptors that influence gene expression and regulate the immune 
functions of clearance, autophagy, phagocytosis, and recruitment of other immune cells through 
downstream signaling molecules.  
Toll-like receptors (TLR) are transmembrane proteins found on cells that contribute to 
inflammatory responses, such as macrophages or epithelial cells of mucous membranes, which 
recognize PAMP and DAMP and mediate inflammatory effects through downstream signaling 
pathways. TLR have a leucine-rich repeat region and a cytoplasmic tail which has a 
Toll/interleukin-1 (IL-1) receptor (TIR) domain. While TLR are prominently expressed on 
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antigen presenting cells, other cells, including T cells, have been recently shown to express 
particular types of TLR34.  
TLR4 recognizes lipopolysaccharide (LPS), a primary cell wall component of Gram-negative 
bacteria that can contribute to the pathology of post wean syndrome, such as Escherichia coli 
and Salmonella. The bacterial cell wall component spontaneously releases into the host 
circulation, where it interacts with several proteins (TLR4, MD2, CD14, LBP) and initiates the 
innate immune system inflammatory response35,36. LPS is structurally organized into an outer 
polysaccharide region containing the O antigen; and an inner lipid moiety containing lipid A. 
Specifically, TLR4 recognize the lipid A region of LPS as a PAMP37.  
LPS-binding protein (LBP) is a glycosylated acute phase protein in which production in the 
liver is upregulated during the acute phase of a Gram-negative bacterial infection38. LBP 
exclusively binds the lipid A moiety of LPS with high affinity39,40. Once the LBP-LPS complex 
forms, myeloid-origin glycoprotein CD14 binds 41. CD14 is available attached to the cell 
membrane via a glycosylphosphatidylinositol anchor (mCD14) or as a soluble form (sCD14)  
released from cells. sCD14 can bind LPS directly without LBP, and then the sCD14-LPS 
complex can activate cells that are lacking mCD14, such as endothelial cells and fibroblasts42. 
CD14 requires a receptor complex, TLR4/MD2, to initiate signal transduction and downstream 
inflammatory mediators.  TLR4 associates with soluble glycoprotein MD2, which is required for 
TLR4 activation and LPS-sensing43. LPS, in conjunction with LBP and CD14, is delivered to 
TLR4/MD2 on the cell membrane, and the lipid A moiety is recognized by MD2 and results in 
signal transduction cascades within the cell44. 
The MyD88-dependent and independent pathways initiate a pro-inflammatory response 
mediated by nuclear factor (NF)-ĸB binding to promoters that regulate inflammatory genes. 
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Following the MyD88-dependent pathway, after ligand binding the TLR/IL-1R dimerize and 
undergo a required conformational change to recruit downstream signaling molecules including 
adaptor molecule myeloid differentiation primary-response protein 88 (MyD88), IL-1R-
associated kinases (IRAK), transforming growth factor-β (TGF-β)-activated kinase (TAK1), 
TAK1-binding protein 1 (TAB1), TAB2 and tumor-necrosis factor (TNF)-receptor-associated 
factor 6 (TRAF6)33,45. The conformational change of TLR/IL-1R recruits MyD88 to the 
cytoplasmic TIR domain, where it facilitates the interaction of IRAK4 with the receptor 
complex. Following this binding, IRAK4-mediated phosphorylation of specific residues in the 
activation loop of IRAK1 initiates the kinase activity of IRAK1. The activated IRAK1 auto-
phosphorylates, thereby allowing TRAF6 to bind to the structure, the IRAK1-TRAF6 complex 
leaves the receptor and interacts at the plasma membrane with another preformed complex 
consisting of TAK1, TAB1, and TAB2 or TAB3. The interaction between the two complexes 
induces phosphorylation of TAK1 and TAB2 or 3, which will then translocate with TRAF6 and 
TAB1 to the cytoplasm of the cell. TAK1 is activated in the cytoplasm, and in turn activates IĸB 
kinases (IKK), which phosphorylate IĸB, and lead to their degradation and the ultimate release of 
the transcription factor NF-ĸB and subsequent cytokine production. Conversely, in the MyD88-
independent pathway, TLR3 and TLR4 activate TRIF-dependent signaling, which activates NF-
ĸB and IRF3, resulting in the induction of pro-inflammatory cytokines and type 1 interferon. 
 
LPS-induced cellular response 
Once NF-ĸB has translocated to the nucleus, inflammatory mediators like cytokines and 
chemokines are differentially activated based on the cell type. The innate immune response 
results in a rapid burst of pro-inflammatory cytokines into the surrounding tissue and circulation, 
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and recruits effector cells, such as neutrophils, to travel to the site of infection for assistance in 
the clearance of the pathogen. The major secreted pro-inflammatory cytokines following an LPS 
challenge include tumor necrosis factor-α (TNFα), interleukin (IL)-1β, and IL-6. TNFα and IL-
1β share several biological roles, such as activating neutrophils, and high concentrations in the 
circulation of these two cytokines can result in numerous pathophysiological effects such as 
fever and multiple organ failure46–48. IL-6, while still pro-inflammatory, is considered to be less 
potent than TNFα or IL-1β, and can be induced by those two cytokines. IL-6 can also be anti-
inflammatory by inhibiting the synthesis of TNFα and IL-1β and inducing the release of soluble 
TNF receptors49. IL-4 and IL-10 are two major anti-inflammatory cytokines released following 
TLR4 stimulation. IL-4, mainly synthesized by activated T-lymphocytes, has biological roles in 
B cell proliferation and inhibition of inflammatory cytokine production50,51. IL-10 diminishes 
excessive inflammatory reactions, reduces antigen presentation, and inhibits T cell activation52. 
Generally secreted from mononuclear phagocytes, endothelial and epithelial cells, IL-8 is a key 
mediator in the inflammatory response53. A product and inducer of NF-ĸB, IL-8 secretion is also 
induced by LPS, TNFα, and IL-1β. In the extracellular environment, IL-8 results in the 
chemoattraction of neutrophils, the release of granule enzymes, and respiratory burst of 
neutrophils54.  
In nearly all cell types, LPS, TNFα, and IL-1β also upregulate the expression of inducible 
nitric oxide synthase (iNOS)55. iNOS exerts indirect anti-microbial and anti-viral effects in low 
concentrations and is an essential regulator of homeostasis56,57. However, overproduction of 
iNOS leads to cytotoxicity and mediates cell apoptosis, promotes tumor angiogenesis, and can 




LPS and Post-weaning Syndrome 
Following weaning, changes in diet and environment induce a fasting period in the 
piglets, which leads to decreased Lactobacilli in the gastrointestinal tract, thereby allowing 
increased populations of E. coli and shedding of LPS. Increased LPS acts through TLR4 to 
activate NF-ĸB and lead to the release of pro- and anti-inflammatory mediators. The release of 
pro-inflammatory cytokines causes morphological and functional changes in the gastrointestinal 
tract59. TNFα and IL-8 negatively influence the permeability of intestinal cells and the transport 
of ions and nutrients60,61. Specifically, TNFα gene expression decreases Na+ / K+ -ATPase 
activity leading to fluid accumulation in the small intestine and is a significant driver behind 
post-wean diarrhea62,63. Released LPS also causes structural changes in the small intestine by 
disrupting the structure of tight junctions and causing the internalization of tight junction protein 
occludin, which allows pathogens to cross into systemic circulation61,64. TNFα increases 
intestinal permeability by disrupting expression of claudins and occludins and by altering the 
lipid environment of phospholipid membranes to displace tight junction proteins65,66. Increased 
bacterial translocation drives the inflammatory response, and continuous production of pro-
inflammatory cytokines leads to the suppression of important intestinal anti-inflammatory 
mediators like IL-10. Overproduction of pro-inflammatory and suppression of anti-inflammatory 
cytokines modulate the immune response and lead to inappropriate activation of antigen-
presenting cells and intolerance to specific antigens, as well as limiting the proliferation of T 
cells52.  
Inflammatory mediators play a vital role in initiating a more robust immune response, 
activating other immune cells, and maintaining homeostasis. However, it is clear that 
overexpression of the immune response is deleterious. Therefore, many LPS therapies are 
11 
 
targeted at increasing immune surveillance and antigen presentation while preventing the over 
elicitation of these inflammatory mediators.  
 
Alkaline Phosphatase 
Alkaline phosphatases (AP) are homodimeric enzymes that catalyze the hydrolysis of 
monoesters of phosphoric acid and transphosphorylation reactions. AP are naturally occurring in 
the mammalian body and are divided into four types: tissue non-specific AP (TNAP), placental 
AP (PLAP), germ cell AP (GCAP) and intestinal AP (IAP)67. Intestinal alkaline phosphatase is a 
glycoprotein anchored in the apical membrane of the small intestine and is found in the highest 
levels in the duodenum, followed by the jejunum and ileum. IAP has several biological roles, 
including being a negative regulator of intestinal fat absorption, maintaining bicarbonate 
secretion and pH balance, and exerting immune-protective effects68,69. Expression of IAP is 
dependent upon enterocyte differentiation; therefore, the enzyme is often used as a biomarker for 
abnormal digestive and absorptive functions in the small intestine. 
Specific proteins in tight junction adhesion complexes reside in lipid rafts on the apical 
membrane of the intestinal epithelial cells, and during lipid absorption, IAP is located in the 
same area. Lipid rafts are a unique subdomain of the plasma membrane and are enriched in 
glycosphingolipids, cholesterol, and sphingomyelin. When Caco-2 cells, an intestinal cell line, 
were treated with the pro-inflammatory cytokine IFN-γ, the disruption of lipid rafts preceded 
intestinal permeability failure70. The study also confirmed this in dextran sulfate sodium (DSS) 
induced colitis in mice and human ulcerative colitis patients. Treatment of another intestinal 
epithelial cell line, T84, with TNFα and IFN-γ resulted in altered lipid composition of lipid rafts 
and loss of barrier function by displacing occludins65. Another study determined that these lipid 
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rafts were released from the tips of the microvilli of intestinal epithelial cells and concluded that 
the shedding is one mechanism for distributing IAP activity throughout the mucosal layer of the 
gut71. Finally, the same study also reported that both IAP expression and luminal vesicle 
production and shedding upregulated in the presence of Gram-negative bacteria. 
The toxicity of LPS, specifically the lipid A moiety, is dependent upon its 
phosphorylation state72. Since IAP is found in the small intestine and catalyzes the hydrolysis of 
phosphoric groups, and the toxicity of LPS is dependent upon the phosphorylation state, it stands 
to reason that IAP could dephosphorylate LPS.  
The ability of IAP to dephosphorylate LPS, at physiological pH, and to reduce the toxic 
effects in vivo was first shown in 199773,74. A significant role of alkaline phosphatase in vivo is to 
detoxify bacterial LPS that is present in the intestinal lumen. High levels of IAP can control 
LPS-induced inflammation in two ways: by dephosphorylating LPS and decreasing TLR4 
stimulation, and by preventing NF-ĸB translocation to the nucleus by inhibiting the 
phosphorylation of two critical proteins in the pathway, IĸBα and RelA/p6575. IAP activity has 
been shown to increase in the presence of Gram-negative bacteria or with LPS alone, and Gram-
positive bacteria that lack LPS did not affect IAP gene expression76. The efficacy of IAP to 
dephosphorylate LPS and reduce its toxic effects have been shown many times in experiments 
with IAP administered intra-peritoneal and attenuating LPS toxicity75,76. Furthermore, oral 
administration of IAP prevented GIT tissue damage and pro-inflammatory cytokine expression 
that was induced by DSS in mice77.  
During weaning, piglets go through a fasting period as their immature digestive and 
immune systems are maturing, and it is well known that fasting dramatically decreases IAP 
activity78. Expression of IAP was also significantly reduced in weaned piglets compared to 
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suckling, and this contributes to the increased occurrence of GIT pathogens79. Fasting also 
decreases Lactobacillus populations which allow overpopulation of Gram-negative bacteria, and 
treatment with the probiotic Lactobacillus casei stimulated IAP activity80. IAP’s ability to reduce 
bacterial translocation and attune commensal microbiota may be an ancillary effect of pH 
regulation, as an alkaline microenvironment is unfavorable for the growth of pathogens68.  
Porcine epidermal growth factor (pEGF) is found in sow milk and contributes to 
postnatal gut mucosal growth and development, and a recent study showed that supplementing 
weaned pigs with exogenous pEGF caused an increase in gene expression and protein activity of 
digestive enzymes in the GIT, including IAP81,82. Therefore, weaning contributes to a decrease in 
expression and activity of immuno-protective enzyme intestinal alkaline phosphatase, but 
exogenous supplementation exerts protective effects against LPS-mediated disease. 
 
Monophosphoryl Lipid A 
LPS contains two phosphate groups in the lipid A moiety, and interactions with alkaline 
phosphatases cause the release of inorganic phosphate and the formation of monophosphoryl 
lipid A (MPLA)74,83. The absence of the 1-phosphate on MPLA is believed to weaken the 
dimerization of TLR4/MD2, which presumably induces a structural change in the TLR4 receptor 
complex that alters the recruitment of adaptor proteins84. MPLA has distinct signaling properties 
as it predominantly activates the TLR4/TRAM-TRIF pathway over the more inflammatory 
MyD88-dependent pathway85. This difference in observed effects after exposure to LPS or 
MPLA could be explained as an active suppression, rather than a passive loss, of pro-
inflammatory activity. MPLA is classified as a TLR4 agonist, meaning it signals through 
TLR4/MD2 and maintains the immuno-stimulatory properties of LPS but with reduced toxicity 
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and elicited inflammatory response.  Specifically, MPLA increases antigen presentation of 
antigen presenting cells, like dendritic cells or macrophages, and subsequent activation of the 
MHC in effector T and B cells86.   
The gut epithelium has specialized epithelial cells called microfold cells (M cells) that 
transport luminal antigens and bacteria to underlying antigen presenting cells and reside in the 
follicle-associated epithelium surrounding Peyer’s patches. Peyer’s patches are aggregated 
lymphoid follicles and are part of the gut-associated lymphoid tissue (GALT), which consists of 
both aggregated and isolated lymphoid follicles87. The GALT accounts for about 70% of the 
body’s immune system and is the largest lymphoid organ. Exposing M cells to MPLA increases 
their ability to uptake antigens and present them to lymphocytes in the GALT, which is vital to 
mounting humeral and cell mediates responses88.  Furthermore, increasing the antigen uptake 
ability of one component of the GALT may increase the antigen presentation ability of the entire 
tissue. Due to its ability to increase antigen uptake and presentation of APC, MPLA dramatically 






Weaning is the most stressful part of a pigs’ life due to extreme and sudden 
environmental and physical stressors. These effects can lead to detrimental morphological and 
functional changes in the gastrointestinal tract, which promote microbial dysbiosis, increased gut 
permeability and bacterial translocation, malnutrition, and inflammation. The sudden increase in 
pathogenic bacteria, such as E. coli and Salmonella, leads to increased TLR4 stimulation and 
cytokine release; promote more inflammation, diarrhea and decreases immune function. LPS 
toxicity is dependent upon its phosphorylation state, and intestinal alkaline phosphatase has been 
shown previously to dephosphorylate LPS and change its ability to bind TLR4 resulting in 
altered signal transduction, thus reducing the innate immune response.  
Current literature on the benefits of alkaline phosphatase and monophosphoryl lipid A 
utilizes the mammalian IAP isoform which is often derived from swine or bovine. Obtaining IAP 
from a mammalian host requires euthanizing the animal and scraping the mucosa of the small 
intestine, followed by various digestion and isolation techniques. This process requires land and 
money to house the animals and feed for them, produces negative environmental output, and has 
enzymatic variability between animals due to diet, disease state, and genetics. Furthermore, it 
requires large numbers of animals for a small amount of enzyme. Overall, it results in a high 
economic and environmental cost for a highly variable product. 
Microbial enzymes are used in a variety of fields and have a large number of 
biotechnological applications. Bacterial hosts can be engineered to rapidly and efficiently 
overexpress recombinant enzymes and then cultured in large quantities to produce a substantial 
amount of the desired enzymes91. The fast growth rate and simple requirements of microbes 
make them a more sustainable, economically, and environmentally friendly option. Microbial-
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derived enzymes are rapidly becoming more popular than conventional enzymatic production 
methods due to their consistency, ease of optimization, regular supply, and greater catalytic 
activity92.  Recently, a microbe-derived alkaline phosphatase has been produced that purportedly 
can detoxify Gram-negative bacteria LPS and provide the same GIT benefits and immune-
stimulatory effects as mammalian-derived IAP.  
Therefore, it stands to reason that exogenous supplementation of a microbe-derived AP 
could interact with the increased populations of Gram-negative bacteria associated with weaning 
and detoxify their LPS products and strengthen gastrointestinal barrier function. This interaction 
would lead to a decreased inflammatory response, decreased morphological changes, 
microbiome symbiosis, increased nutrient absorption and ion channel usage, and an overall 
decreased mortality and increased growth rate during weaning.  The goal of this thesis was to 
determine the ability of microbe-derived AP (MAP) to reduce the toxic effects of LPS in vitro 
and in vivo, and if exogenous supplementation of MAP during the post-weaning phase would 
result in increased intestinal IAP expression and activity, and protect against post-weaning 






CHAPTER 2: MICROBIAL-DERIVED ALKALINE PHOSPHATASE DETOXIFIES 
LIPOPOLYSACCHARIDE AND ALTERS SICKNESS BEHAVIOR AND INFLAMMATORY 
RESPONSE IN WEANING PIGS 
2.1 Abstract 
Mammalian-derived intestinal alkaline phosphatase (IAP) detoxifies lipopolysaccharide 
(LPS) but it is not readily available for commercial application. Therefore, we sought to 
determine the ability of a microbial-derived alkaline phosphatase (MAP) to detoxify LPS and 
reduce the inflammatory response in vitro and in vivo. Compared to Salmonella enterica LPS or 
Escherichia coli LPS, MAP-detoxified LPS-stimulated primary alveolar macrophages had 
reduced transcription of pro-inflammatory cytokines TNFα, IL-6, and IL-1β, and anti-
inflammatory cytokine IL-10 (P<0.001). Weaned piglets injected i.p. with MPLA or saline had 
no differences in serum TNFα, IL-6, IL-10, or IL-4 concentrations. LPS-injected piglets had 
higher serum TNFα (P=0.005) and IL-6 (P=0.006) levels than control piglets at peak-challenge, 
and LPS-induced TNFα remained elevated 4 hours post-injection (P=0.003). LPS injected piglets 
had serum IL-10 and IL-4 as compared to control (P=0.025; P=0.045) and MPLA treated pigs 
(P=0.006; P=0.05). LPS treatment upregulated TNFα transcript in the spleen, as compared to 
control (P=0.006) and (P=0.029) MPLA treated piglets. LPS treatment caused sickness behavior 
as measured by decreased feed intake (P=0.031) and lethargy; however, MPLA did not induce 
behavioral changes. Furthermore, novel findings comparing IAP and MAP, show that MAP has 
an increased efficacy of detoxifying LPS and ameliorating macrophage inflammatory responses 
in vitro. IAP-detoxified LPS-treated primary alveolar macrophages had increased gene 
expression of TNFα, IL-1β, and IL-10 compared to cells stimulated with MAP-detoxified LPS 
(P<0.001). Together these results support the efficacy of MAP to detoxify both S. enterica and E. 
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Bacterial endotoxins are associated with sepsis and septic shock and potentiate other diseases 
such as Crohn’s disease, cystic fibrosis, and heart disease93. Lipopolysaccharide (LPS) is one 
such endotoxin and is present on the cell wall of Gram-negative bacteria, such as Salmonella 
enterica and Escherichia coli. Upon gastrointestinal infection, LPS can be spontaneously 
released into host circulation and initiate an inflammatory response marked by fever, decreased 
feed intake, and increased diarrhea35,36. In neonates the immature immune system can be 
overcome, resulting in an overproduction of pro-inflammatory cytokines that modulate the 
immune response and disrupt tight junction proteins in the gut, leading to further microbial 
translocation64–66. The innate immune response is initiated when homeostatic functions are 
perturbed and surveilling immune cells recognize patterns associated with these perturbations, 
called danger-associated molecular patterns (DAMP) and pathogen-associated molecular patterns 
(PAMP). PAMP and DAMP bind to specific receptors that influence gene expression and 
regulate the immune functions of clearance, autophagy, phagocytosis, and, through downstream 
signaling molecules, recruit other immune cells. 
Toll-like receptors (TLR) are transmembrane proteins found on cells that contribute to 
inflammatory responses, such as macrophages or epithelial cells of mucous membranes, which 
recognize PAMP and DAMP and mediate inflammatory effects through downstream signaling 
pathways. TLR4 recognizes LPS and initiates the innate immune systems’ inflammatory 
response35,36. LPS is structurally organized into an outer polysaccharide region containing the O 
antigen; and an inner lipid moiety containing lipid A. Specifically, TLR recognize the lipid A 
region of LPS37. TLR4 signaling, through MyD88 or TRIF/TRAM signaling pathways, 
ultimately results in a rapid burst of pro-inflammatory cytokines into the surrounding tissue and 
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circulation and recruits effector cells, such as neutrophils, to travel to the site of infection for 
assistance in the clearance of the pathogen. The major pro-inflammatory cytokines that are 
secreted following an LPS challenge are TNFα, IL-1β, and IL-6. IL-1β and TNFα share several 
biological roles, such as activating neutrophils, and high concentrations in the circulation of 
these two cytokines can result in numerous pathophysiological effects such as fever and multiple 
organ failure46–48. IL-6, while still pro-inflammatory, is considered to be less potent than TNFα 
or IL-1β, and can be induced by those two cytokines. IL-6 has also been implicated in multiple 
organ failure. IL-4 and IL-10 are two major anti-inflammatory cytokines released following 
TLR4 stimulation. IL-4, mainly synthesized by activated T-lymphocytes, has biological roles in 
B cell proliferation and inhibition of inflammatory cytokine production50,51. IL-10 diminishes 
excessive immune reactions, reduces antigen presentation, and inhibits T cell activation 52. 
However, overproduction of IL-4 and IL-10 can slow pathogen clearance and potentiate 
immunopathology.  
Mammalian enteric brush border enzyme intestinal alkaline phosphatase (IAP) has been 
shown to exert protective effects in the gut, by detoxifying LPS in the intestinal lumen. IAP is a 
glycoprotein anchored in the apical membrane of the small intestine and has several biological 
roles including being a negative regulator of intestinal fat absorption, maintaining bicarbonate 
secretion and pH balance, and exerting immune-protective effects68,69. The toxicity of LPS is 
highly dependent upon its phosphorylation state, and removal of one of the two phosphate 
groups by IAP reduces the toxic effects of LPS in vitro and in vivo73,74. High levels of IAP can 
control LPS-induced inflammation in two ways: by dephosphorylating LPS and decreasing 
TLR4 stimulation, and by preventing NF-ĸB translocation to the nucleus by inhibiting the 
phosphorylation of two critical proteins in the pathway, IĸBα and RelA/p6575. When an alkaline 
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phosphatase removes the 1-phosphate on LPS, it yields monophosphoryl lipid A (MPLA)83,84. 
MPLA is known to activate the TLR4/TRAM-TRIF pathway predominantly over the more 
inflammatory MyD88-dependent pathway85. MPLA works as a TLR4 agonist and maintains the 
immune-stimulatory properties of LPS, but with reduced toxicity and inflammatory response. 
MPLA has been shown to increase antigen presentation of circulating antigen presenting cells 
and M cells in gut-associated lymphoid tissue86,88.  
Microbial enzymes are utilized in a variety of fields and have a large number of 
biotechnological applications. Bacterial hosts engineered to rapidly and efficiently overexpress 
recombinant enzymes can be used to produce a substantial amount of the desired enzyme91. 
Microbial-derived enzymes are quickly becoming more popular than conventional enzymatic 
production methods due to their consistency, ease of optimization, regular supply, and greater 
catalytic activity92. Recently, a microbe has been manipulated to produce alkaline phosphatase 
that can purportedly detoxify Gram-negative bacteria LPS and provide the same GIT benefit and 
immune-stimulatory effects as IAP. The objectives of the study were to assess the ability of a 
microbial-derived alkaline phosphatase (MAP) to detoxify LPS at physiological pH and reduce 
the inflammatory effects of LPS, as well as the potential immuno-stimulatory properties of 
MPLA. Using mammalian-derived IAP, we also tested whether MAP would have greater 
detoxification ability than IAP, and if the subsequent MPLA products would have differences in 
their elicited inflammatory responses. We hypothesized that MAP would detoxify LPS and elicit 
lower levels of pro-inflammatory cytokines from both the immortalized RAW264 cell line and 
primary pig alveolar macrophages. We also hypothesized that i.p. administration of MPLA 
would result in lower levels of circulating cytokines and decreased sickness behavior in weaning 
piglets, compared to LPS.   
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2.3 Materials and Methods 
Isolation of primary alveolar macrophages  
 Pulmonary organs with the trachea clamped were obtained from 6-month old cross-bred 
Yorkshire-Landrace male barrows from the University of Illinois Meats Laboratory. The lungs 
were filled with 500 mL of RPMI 1640 supplemented with 500 IU/mL penicillin/streptomycin. 
Lungs were massaged approximately 2 minutes, and the lavage fluid was aspirated with a 25-mL 
pipette and collected in a sterile 50 mL conical tube. The lavage was repeated twice and always 
yielded a white, foamy fluid. The collected suspension was centrifuged at 4°C at 400×g for 10 
minutes and the supernatant discarded. The cell pellet was washed with 2.0 mL of ammonium 
chloride (0.83% NH4Cl in 0.1% KHCO3-0.01 M EDTA) to lyse red blood cells. The suspension 
was then washed three times with RPMI-1640 plus 100 IU/mL penicillin/streptomycin. 
Following washes, the pellet was suspended in RPMI 1640 containing 10% FBS, 4mM HEPES, 
1× minimum essential medium (MEM), nonessential amino acids, 1 mM sodium pyruvate, and 
100 IU/mL penicillin/streptomycin. Cells were seeded onto 12-well culture plates at a 
concentration of 106 / well and allowed to adhere for 24 hours in a humidified incubator at 5% 
CO2 and 40°C, then washed twice to remove cellular debris and non-adherent cells. The cells 
were then treated as alveolar macrophages and allowed to rest for 2 hours prior to stimulation.  
 
RAW264 and primary alveolar macrophage culture and treatments 
Initially, the immortalized pig alveolar macrophage cell lines CRL-2843/CRL-
2844/CRL-2855 (ATCC) were utilized but failed to develop normal morphology during standard 
growth periods and had an aberrant inflammatory response when treated with LPS 
(Supplemental Fig 2.1). Therefore, it was determined to use immortalized murine macrophage 
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cell line RAW264 (ATCC® TIB-71) for all initial experiments. Preliminary studies with 
RAW264 showed that 100 ng/mL S. enterica LPS or E. coli LPS was the optimal concentration 
for eliciting a robust inflammatory response without killing the cells. The viability of RAW264 
and porcine alveolar macrophages was evaluated using the Thermo Scientific Pierce Lactate 
Dehydrogenase Cytotoxicity Assay Kit (Thermo Scientific, Rockford, IL, USA) in accordance 
with the manufacturer’s instructions was and was <10%. A similar dose-response curve was 
created for treating RAW264 with MAP to determine if the new compound was toxic. Finally, 
LPS was incubated with increasing concentrations of MAP. Incubating LPS and MAP in a ratio 
of 1 IU/mL MAP: 1 µg/mL LPS was determined to create optimum detoxification. Both S. 
enterica and E. coli LPS serotypes were used and are presented in separate figures for 
clarification.    
RAW264 cells were maintained in 75-cm2 tissue culture flasks (TPP) in DMEM 
supplemented with 10% FBS and 100 units/mL penicillin/streptomycin at 37°C in a humidified 
incubator under 5% CO2. For stimulation, cells were plated in 12-well culture plates overnight at 
a concentration of 106 / well. Cells were then washed and allowed to rest for two hours prior to 
treatment. RAW264 cells were stimulated with 100 ng/mL Salmonella enterica serotype 
Typhimurium LPS (L2262; Sigma-Aldrich, St. Louis, MO, USA), 0.10 IU/mL MAP (Elanco 
Animal Health, Greenfield, IN, USA), 0.10 IU/mL IAP (P0114; CAS 9001-78-9; EC 3.1.3.1; 
Sigma-Aldrich), 100 ng/mL IAP-derived MPLA (iMPLA), or 100 ng/mL MAP-derived MPLA 
(MPLA; see LPS Challenge). In separate but identical trials, RAW264 cells were stimulated with 
100 ng/mL of E. coli LPS (L3137; serotype 0127:B8, Sigma-Aldrich) or detoxified E. coli LPS 
(MPLA). IAP-derived MPLA was prepared using the same S. enterica or E. coli serotypes and 
protocol as listed under Piglet Immune Challenge. Primary pig alveolar macrophages were plated 
24 
 
on 12-well plates at a concentration of 106 / well and supplemented with 10% FBS, 100 IU/mL 
penicillin/streptomycin and maintained at 40°C in a humidified incubator under 5% CO2. 
Primary alveolar macrophages were stimulated for four hours with 100 ng/mL S. enterica LPS, 
0.10 IU/mL MAP, 0.10 IU/mL IAP (Sigma), 100 ng/mL IAP-derived MPLA, or 100 ng/mL 
MAP-derived MPLA. In separate but identical trials, primary alveolar macrophages were 
stimulated with 100 ng/mL E. coli or detoxified versions of E. coli LPS. Cells were harvested 4 
hours post-treatment, and both media and cells were collected, and cells were put directly in 
Trizol reagent (Invitrogen, Grand Island, NY, USA). 
 
Animals 
 Eighteen Yorkshire piglets from the University of Illinois swineherd were naturally 
farrowed and weaned at 21 days of age. Results are from three separate cohorts. After weaning, 
piglets were kept in a 312 cm L × 130 cm W × 80 cm H wooden pen in sex-matched littermate 
pairs. Piglets were kept on the premises of University of Illinois Swine Research Center and 
allowed 48 hours to acclimate before injections. Room temperature was kept at 28°C and piglets 
were provided supplemental heat. After completion of the study (postnatal day 23, 4 hours post-
injection) piglets were anesthetized using a telazol:ketamine:xylazine solution (50 mg of 
tiletamine plus 50 mg of zolazepam reconstituted with 2.5 mL ketamine [100 mg/mL] and 2.5 
mL xylazine [100 mg/mL]; Fort Dodge Animal Health, Fort Dodge, IA); the anesthetic 
combination was administered i.m. at 0.03 ml/kg BW. After verifying anesthetic induction, 
piglets were euthanized via i.c. administration of sodium pentobarbital (1 mL/4.5 kg BW; Fatal 
Plus®, Vortech Pharmaceuticals, Dearborn, MI, USA). All animal procedures were approved by 




 Piglets were divided into three treatment groups for injections controlling for sex, litter of 
origin, and body weight: vehicle, lipopolysaccharide (LPS), and monophosphoryl lipid A 
(MPLA). Salmonella enterica serotype Typhimurium LPS (L2262; Sigma-Aldrich) was utilized 
for the LPS treatments of piglets. To dephosphorylate LPS into MPLA, LPS was incubated with 
MAP, supplemented with 1.0 mM MgCl2+ and 0.1 mM zinc sulfate monohydrate, at pH 8.5 in 
the ratio of 1 IU MAP:1 µg LPS, as previously described by Bates et al.94. In summary, LPS was 
incubated with MAP for 4 hours at 40°C. Filter-sterilized solutions of LPS and vehicle were 
mock-treated by being incubated under the same conditions without the addition of MAP. After 
the final incubation, the LPS-MAP mixture was treated as monophosphoryl lipid A (MPLA). 
LPS and MPLA were injected i.p. at a dose of 10 µg LPS/kg BW. Previous work in our lab has 
shown this dose of LPS induces an increase in plasma TNFα that peaks at 4 hours post-
injection95. Vehicle was administered i.p. at the same volume/BW. Treatments were 
administered at 0800 for all cohorts. Piglets were euthanized 4 hours post-injection and serum 




 Behavior was digitally recorded throughout the four-hour time period using a Sony DCR 
SR300 camera mounted above the pen. Time spent eating and inactive were estimated from the 
video records by instantaneous scan sampling at one-minute intervals. Behaviors were scored by 
a trained experimenter blinded to treatment. A pig was considered to be eating if standing with 
head in the trough, and a pig was considered inactive if it was lying down. Feed was removed 3 
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hours prior to injections and placed back in pen 45 minutes post-injection to control for variation 
in food motivation. 
 
Gene Expression 
Total RNA from macrophages were isolated using the Tri Reagent protocol (Invitrogen). 
Complimentary DNA was synthesized using a high-capacity RT kit (Applied Biosystems, Grand 
Island, NY, USA) according to the manufacturer’s instructions. Quantitative real-time PCR was 
performed using the Applied Biosystems Taqman Gene Expression Assay protocol, and relative 
gene expression was determined from the fluorescent data on an ABI PRISM 7900HT sequence 
detection system (PerkinElmer, Waltham, MA, USA). All mouse primers for quantitative PCR 
were obtained from Integrated DNA Technologies (Coralville, IA, USA). Genes of interest 
(Supplemental Table 2.1) were compared against reference controls. RAW264 cells were 
analyzed with the reference gene GAPDH (NM_008084), and primary alveolar macrophages 
were compared to reference gene RPL19 (Ss03375624_g1). PCR conditions included 50°C for 2 
minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and 1 cycle at 60°C for 1 
minute. Gene expression was determined using the 2-ΔΔCt calculation method as previously 
described96. Data are expressed as fold change versus controls. Tissue collected from the piglets 
at the end of the 4-hour time-point were also used to assess steady-state mRNA levels utilizing 
the method and primers mentioned above for primary pig alveolar macrophages. In brief, spleen 
and liver samples were collected and flash frozen.  Tri Reagent protocol (Invitrogen) was used 
for total RNA isolation with 50 mg/tissue per animal. Complementary DNA was synthesized, 
and RT-qPCR ran for relative gene expression of TNFα, IL-1β, IL-6, and IL-10. RPL-19 was 
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used as a housekeeping control gene and data compared using the 2-ΔΔCt calculation method96, 
with data presented as fold change versus control. 
 
Cytokine Measurements 
ELISA were used to determine serum and culture medium concentrations of IL-10, IL-4, 
IL-6, and TNFα according to manufacturer’s instructions (R&D Systems; Minneapolis, MN, 
USA and Thermo Fisher; Carlsbad, CA, USA). The interassay coefficient of variance was <5% 
for all assays conducted. 
 
Statistics 
Data were analyzed utilizing one-, two-, or three-way ANOVA with or without repeated 
measures, followed by Tukey’s multiple comparisons tests when appropriate. Statistical 
significance was set at p≤0.05. Analysis was performed using GraphPad Prism version 7.00 for 
Windows (GraphPad Software, La Jolla, CA) or SASTM 9.4 software (SAS Institute, Cary, NC, 
USA). All data are expressed as means ± standard error of the mean. Treatments with different 










Supplemental Table 2.1. Quantitative real-time PCR primer information 
Gene Classification Species Accession numbera Assay identificationb,c 
GAPDH Reference mouse NM_008084 Mm.PT.39a.1b 
TNFα Pro-inflammatory mouse NM_013693 Mm.PT.58.29509614b 
IL-6 Pro-inflammatory mouse NM_031168 Mm.PT.58.13354106b 
IL-1β Pro-inflammatory mouse NM_008361 Mm.PT.58.41616450b 
IL-10 Anti-inflammatory mouse NM_010548 Mm.PT.58.23604055b 
RPL-19 Reference pig AF435591 Ss03375624_g1c 
TNFα Pro-inflammatory pig NM_214022 Ss03391318_g1c 
IL-6 Pro-inflammatory pig NM_214399 Ss03384604_u1c 
IL-1β Pro-inflammatory pig NM_214055 Ss03393804_m1c 
IL-10 Anti-inflammatory pig NM_214041 Ss03382372_u1c 
aNCBI GenBank accession number.    
bIDT Gene Expression Assay identification number.   




Microbial-derived alkaline phosphatase detoxifies S. enterica and E. coli LPS  
 It was previously reported that mammalian intestinal alkaline phosphatase (IAP) is 
capable of detoxifying LPS75,77,94. However, the ability of microbe-derived alkaline phosphatase 
to detoxify LPS is unknown. The method of detoxifying LPS, through interaction with alkaline 
phosphatase, was adapted from Bates et al76 to determine the capacity of microbe-derived 
alkaline phosphatase (MAP) to detoxify LPS and reduce LPS-induced macrophage responses in 
vitro.  For clarification, following the incubation steps described above, the MAP-LPS mixture 
was considered to be monophosphoryl lipid A or MPLA.  
As previously reported by others, pre-treating Salmonella LPS with MAP resulted in 
downregulated mRNA in RAW264 macrophages for pro-inflammatory cytokines TNFα, IL-6, 
and IL-1β and anti-inflammatory cytokine IL-10 as compared to Salmonella LPS treatment alone 
(Fig 2.1a-d). Furthermore, treatment of RAW264 macrophages with MAP alone had no effect as 
compared to vehicle control (P=0.999). Every cytokine mRNA assessed was higher in RAW264 
cells treated with Salmonella LPS compared to control (P<0.005) while MPLA was not different 
from control. RAW264 supernatant was collected, and TNFα and IL-6 protein concentrations 
determined (Fig 2.1e-f). TNFα protein concentration was elevated by Salmonella LPS treatment 
(P<0.001) and to a lesser extent with MPLA treatment (P=0.019). Salmonella LPS treatment 
elevated TNFα protein levels as compared to MPLA (P=0.001). IL-6 protein concentration from 
Salmonella LPS treated RAW264 cells was elevated compared to controls (P<0.001) and MPLA 
treatments (P<0.001).  Salmonella MPLA treatment was not inflammatory enough to cause a 
significant change from controls and had a lower concentration of IL-6 (P=0.240). Similar results 
were obtained using LPS derived from E. coli. RAW264 macrophages had higher cytokine 
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production from treatment with E.coli LPS as compared to control treatments for TNFα, IL-6, 
IL-1β, and IL-10 (P<0.001) (Fig 2.2a-d). Furthermore, MPLA derived from E.coli LPS elicited 
lower mRNA expression than E. coli LPS treatment alone for TNFα (P=0.003), IL-6 (P=0.04), 
IL-1β (P=0.037), and IL-10 (P=0.005). The supernatant was collected, and ELISA performed for 
TNFα and IL-6 (Fig 2.2e-f). E. coli LPS upregulated TNFα protein (P<0.001); however, 
detoxified E. coli or MPLA, elicited significantly less protein than LPS (P=0.002). E. coli LPS 
stimulated the release of IL-6 compared to MPLA treatment (P=0.002). These results indicate 
that MAP is adept at detoxifying LPS products from Gram-negative Salmonella and E.coli 









To confirm the results across species and in primary cells, primary pig alveolar 
macrophages were collected and treated with vehicle, 0.10 IU/mL MAP, 100 ng/mL S. enterica 
LPS, or 100 ng/mL of Salmonella MPLA. Cells and supernatant were collected to assess markers 
of inflammation (Fig 2.3a-d). TNFα, IL-6, IL-1β, and IL-10 mRNA expression in primary 
alveolar porcine macrophages was upregulated with LPS (P<0.001) and MPLA treatment, 
however, LPS elicited a greater increase in cytokine expression compared to MPLA (P<0.001). 
These results demonstrate that MAP detoxifies Salmonella LPS, and the resultant MPLA product 
is less inflammatory.  Porcine alveolar macrophage supernatant was subjected to ELISA to 
determine the protein concentration of IL-6 (Fig 2.3e). Both Salmonella LPS and Salmonella 
MPLA elevated IL-6 concentrations (P<0.001); however, Salmonella LPS treatment elicited 
more product than Salmonella MPLA treatment (P<0.001). Again, the above results were 
confirmed using E. coli LPS and MPLA derived from E. coli LPS. Compared to control 
treatment, E. coli LPS upregulated TNFα, IL-6, IL-1β, and IL-10 mRNA abundance in primary 
alveolar macrophages (Fig 2.4a-d). Furthermore, for all measured cytokine gene expression, E. 
coli MPLA treatment was less inflammatory than E. coli LPS (P=<0.001). ELISA analysis of IL-
6 protein in cell culture supernatant confirmed E. coli LPS treatment upregulated IL-6 protein as 
compared to control (P<0.001) and E. coli MPLA treatments (P=0.001) (Fig 2.4e). Together 
these data suggest that MAP detoxifies E. coli LPS at physiological pH and temperature and that 
treatment with the product, MPLA, result in lower mRNA and protein levels of pro- and anti-











MAP differentially detoxifies both Salmonella and E. coli LPS as compared to mammalian-
derived intestinal alkaline phosphatase. 
Current literature supports the efficacy of mammalian-derived intestinal alkaline 
phosphatase (IAP) to detoxify LPS, and the resultant product, mono-phosphoryl lipid A 
(iMPLA) is recognized as a TLR4 agonist and vaccine adjuvant. However, there are no known 
results regarding the use of microbe-derived alkaline phosphatase or its subsequent product after 
incubation with LPS. To determine the ability of a microbe-derived alkaline phosphatase (MAP) 
to detoxify both Salmonella and E.coli LPS, compared to IAP, RAW264 and porcine alveolar 
macrophages were treated with IAP and iMPLA under the same conditions. Unexpectedly, MAP 
exceeded the ability of IAP to detoxify Salmonella LPS as iMPLA elicited a stronger pro-
inflammatory response compared to MPLA (Fig 2.5a-d). For RAW264 macrophages, there were 
no differences between control, MAP, or IAP treatments for all measured cytokines in the 
absence of either LPS or MPLA. TNFα mRNA levels from Salmonella MPLA treatment were 
not different from control (P=0.76). However, both Salmonella LPS and Salmonella iMPLA 
treatment resulted in higher TNFα gene expression (P<0.001). Surprisingly, there was no 
difference between LPS and iMPLA groups (P=0.99), but there was a difference between MPLA 
and iMPLA (P=0.001). These differences in elicited TNFα expression could be due to 
differential detoxifying properties of MAP and IAP. Comparable results were quantified for IL-6 
gene expression. Salmonella LPS treatment elevated IL-6 (P<0.001) and was different from 
MPLA (P=0.001) but not iMPLA (P=0.299). IL-6 gene expression was not different between 
MPLA and iMPLA (P=0.092). Salmonella LPS and iMPLA caused a substantial increase in IL-
1β expression (P<0.001), while Salmonella MPLA only moderately increased mRNA of IL-1β 
(P=0.027). Again, Salmonella MPLA elicited IL-1β expression was lower than Salmonella 
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iMPLA (P=0.027). IL-10 mRNA was increased with Salmonella LPS (P=0.003) and iMPLA 
(P=0.012), but not with MPLA treatment (P=0.605). Salmonella LPS treatment resulted in higher 
IL-10 expression than MPLA (P=0.006) but was not different from iMPLA (P=0.135). 
Furthermore, there was no difference in IL-10 mRNA between iMPLA and MPLA (P=0.254). 
ELISA confirmed TNFα and IL-6 results. Salmonella LPS, iMPLA, and MPLA treatment 
resulted in higher TNFα protein production (P<0.001; P<0.001; P=0.009) (Fig 2.5e). 
Surprisingly, there were no differences between iMPLA and MPLA (P=0.413); however, 
Salmonella LPS treatment increased TNFα concentrations compared to MPLA and iMPLA 
(P<0.001). Only Salmonella LPS treatment caused an increase in IL-6 protein (P=0.007), 
although iMPLA treatment also raised IL-6 levels (Fig 2.5f). Salmonella MPLA-induced IL-6 







Again, the above results were confirmed on RAW264 cells using E.coli LPS and MPLA 
derived from E.coli LPS (Fig 2.6a-f). There were no differences between control, MAP, or IAP 
treatment groups for TNFα, IL-6. IL-1β, or IL-10 gene expression in the absence of immune 
stimulation. E.coli LPS increased gene expression for all measured cytokines as compared to 
control, MAP, and IAP treatment groups (P<0.001). E.coli iMPLA upregulated TNFα and IL-6 
gene expression as compared to MPLA treatment (P=0.006; P=0.014). There were no differences 
between iMPLA and MPLA treatments for IL-1β or IL-10 mRNA levels; however, iMPLA had a 
numerically stronger inflammatory effect. IL-1β gene expression was not different between 
iMPLA and LPS treatment. Cell culture supernatant from RAW264 cells was subjected to 
ELISA for determination of TNFα and IL-6 concentrations (Fig 2.6e-f). E.coli LPS elevated 
TNFα protein levels as compared to both MPLA (P=0.003) and iMPLA (P=0.005); however, 
there were no differences between dephosphorylated LPS types. IL-6 protein levels were 
elevated due to E.coli LPS treatment as compared to MPLA (P=0.015). iMPLA elevated IL-6 
secretion similarly to E.coli LPS. Together these results indicate that microbe-derived alkaline 
phosphatase is a more potent detoxifier of both Salmonella and E. coli LPS than mammalian-







To confirm that these results remain across species and in primary cells, the same 
treatment scheme for both S. enterica and E. coli LPS was applied to primary pig alveolar 
macrophages. For all measured cytokines, both S. enterica (Fig 2.7) and E. coli LPS (Fig 2.8) 
treatment significantly elevated cytokine expression (P<0.001). Induced gene expression of 
TNFα, IL-1β, and IL-10 were not different between Salmonella LPS and iMPLA treatment 
groups, and iMPLA treatment significantly elevated gene expression as compared to MPLA 
treatment (P<0.001; P<0.001; P=0.008) (Fig 2.7a, c-d). There was no difference in treatment-
induced IL-6 gene expression between Salmonella iMPLA and MPLA (Fig 2.7b). IL-6 protein 
was quantified, and Salmonella LPS, iMPLA, and MPLA elevated the concentration as 
compared to controls (P<0.001) (Fig 2.7e). However, MPLA and iMPLA induced IL-6 protein 
were not as high as Salmonella LPS (P<0.001; P=0.002) but were not different. Again, the above 
results were confirmed on porcine alveolar macrophages using LPS and MPLA derived from E. 
coli (Fig 2.8a-e). There were no differences in elicited TNFα, IL-6, and IL-10 gene expression 
between iMPLA and MPLA (Fig 2.8a-b, d). Although iMPLA did not elevate IL-1β gene 
expression as dramatically as LPS (P=0.015), the resultant expression was higher than MPLA 
treatments (P<0.001) (Fig 2.8c). Expectedly, E. coli LPS treatment elevated IL-6 protein levels 
as compared to control treatments (P<0.001) and MPLA (P=0.002) (Fig 2.8e). There were no 
differences in IL-6 concentration between MPLA and iMPLA treatment. These results attest to 
the efficacy of microbial-derived alkaline phosphatase to detoxify LPS as well as, or better than, 
mammalian-derived IAP. Furthermore, the results are congruent across species and two different 










Microbial-derived alkaline phosphatase detoxified Salmonella LPS decreased the 
inflammatory response and altered sickness behavior in weaning piglets 
To determine the ability of MPLA to reduce Salmonella LPS bioactivity in vivo, piglets 
were injected i.p. with saline, LPS, or MPLA.  (Fig 2.9a-d). At 2 and 4 hours post-treatment, 
serum levels of TNFα were higher in LPS-treated pigs than saline piglets (P=0.005; P=0.033, 
respectively), while circulating TNFα was not affected in MPLA-treated pigs.  (P=0.419; 
P=0.093, respectively). MPLA and LPS were not different at any time point. There was a main 
effect of treatment with LPS injected piglets (P<0.001) and MPLA injected piglets (P=0.02) 
having higher TNFα serum levels than saline injected piglets. There were no main effects 
between LPS or MPLA. IL-6 serum levels were elevated at 2 hours post-injection by LPS 
treatment (P=0.005), but MPLA treatment did not elevated IL-6 levels (P=0.112). LPS treatment 
affected cytokine production of TNFα and IL-6 in a time-dependent manner and MPLA 
treatment did not, demonstrating the modulated inflammatory response. IL-6 serum levels had no 
main effects of treatment and there were no interactions between time and treatment for serum 
levels of anti-inflammatory cytokines IL-10 and IL-4.  However, there were main effects of 
treatment with LPS raising circulating IL-10 levels above control (P=0.025) and MPLA piglets 
(P=0.006). IL-4 levels were different between treatments with LPS treatment elevating serum 
levels above both control (P=0.045) and MPLA (P=0.05) treated piglets.  
Since the liver and spleen play a prominent role in the removal of LPS from systemic 
circulation and are important for the acute phase response, gene expression of pro- and anti-
inflammatory cytokines were measured. In the liver, LPS raised TNFα, IL-6, IL-1β, and IL-10 
mRNA higher than MPLA treatment but was not significantly different (Fig 2.9e). Also, TNFα 
was upregulated in the spleen following LPS treatment as compared to control pigs and MPLA 
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pigs (P=0.006; P=0.029, respectively) (Fig 2.9f). LPS treatment also raised splenic IL-6, IL-1β, 
and IL-10 mRNA levels, however, levels were not different from MPLA treatment.  
Behavior was recorded throughout the 4 hours for each cohort to determine if MPLA 
elicited sickness behavior that is well documented for LPS. Total time spent eating and being 
active was calculated per pig and are presented as an average across all cohorts. Throughout the 
4 hour treatment period, piglets injected with LPS spent less time eating than control or MPLA 
groups (P=0.031) (Fig 2.10a). There was a decrease in activity level between treatment groups, 
with control piglets being the most active and LPS piglets being the least active (Fig 2.10b). 











2.5 Discussion and Future Directions 
 
 Lipopolysaccharide (LPS), a Gram-negative bacteria cell component, has long been 
implicated in systemic inflammation and septic shock. It is well known that the toxicity of LPS is 
highly dependent upon its phosphorylation state, and that removal of one of the two phosphate 
groups from the lipid A moiety results in significantly lower toxicity97. In the present study, we 
found that pre-incubation of LPS with microbe-derived alkaline phosphatase (MAP) reduced the 
toxicity of Salmonella and E. coli LPS in vitro and in vivo. Furthermore, novel findings indicate 
that MAP has an increased ability to dephosphorylate LPS, as compared to intestinal alkaline 
phosphatase.  
Secretion of cytokines is necessary for activation of the immune system and migration of 
immune cells to sites of infection. However, LPS can overstimulate TLR4 receptors and lead to 
downstream overexpression of pro-inflammatory cytokines that are detrimental to the host.  As 
macrophages are part of the second line of defense in the body, RAW264 and primary pig 
alveolar macrophages were used to study the capacity of MAP to detoxify LPS in vitro. 
Overproduction of pro-inflammatory cytokines has deleterious effects on homeostatic balance 
and can be lethal. LPS-induced TNFα has long been implicated to be a key mediator in septic 
shock and is necessary and sufficient for liver failure and cytotoxicity46,48,98. An increase in IL-6, 
IL-1β, and IL-10 levels have also been associated with chronic inflammation and sepsis99. MAP-
dephosphorylated Salmonella and E. coli LPS were unable to elicit the same robust inflammatory 
response as native LPS in RAW264 cells or primary alveolar porcine macrophages, as 
demonstrated by reduced pro- and anti-inflammatory cytokine output. These results support 
Polestra et al.(1997), who showed that LPS is a substrate for AP and suggested AP has a role in 
endotoxin dephosphorylation73,74. Furthermore, these results match with Koyama et al. (2002), 
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who showed that LPS toxicity on endothelial cells was diminished in vitro when LPS was 
pretreated with IAP. Interestingly, MAP-detoxified Salmonella and E. coli LPS decreased gene 
expression of IL-10 to control treatment levels in RAW264 macrophages. MAP-detoxified E. 
coli LPS lowered IL-10 gene expression to control levels in primary pig alveolar macrophages. 
Produced by monocytes, lymphocytes, and macrophages, IL-10 is an anti-inflammatory cytokine 
that has been reported to inhibit the expression of pro-inflammatory cytokines TNFα, IL-6, and 
IL-1β100,101. Our results indicate that the lower levels of elicited pro-inflammatory cytokines 
from the MPLA treatments did not require induction of high levels of IL-10 to modulate the 
acute inflammatory response. E. coli and Salmonella LPS treatment alone induced higher levels 
of pro-inflammatory cytokines and thus needed to transcribe IL-10 to, unsuccessfully, inhibit 
cytokine production. These results attest to the ability of MAP to detoxify LPS and modulate the 
inflammatory response. The extent to which this occurs and further effects of this would require 
further research.  
The physiological function of mammalian intestinal alkaline phosphatase is to detoxify 
LPS at the brush border and protect systemic circulation from an antigenic breach. This study 
aimed to compare the efficacy of MAP to reduce the LPS-induced immune response, with the 
ability of IAP to detoxify LPS in vitro. Novel results indicate that MAP has more potent LPS 
detoxification properties than IAP. MAP-detoxified Salmonella LPS was less inflammatory than 
IAP-detoxified LPS as shown by significantly lower TNFα and IL-1β gene expression in 
RAW264 cells and lowered gene expression of TNFα, IL-1β, and IL-10 in primary alveolar 
porcine macrophages. Not only did MPLA evoke lower levels of pro- and anti-inflammatory 
cytokines, but IAP-detoxified Salmonella LPS elicited TNFα and IL-6 gene expression and IL-6 
protein expression that was not different from Salmonella LPS treatments. Similarly, treating 
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RAW264 cells with MAP-detoxified E. coli LPS elicited significantly lower levels of TNFα and 
IL-6 mRNA than IAP-detoxified E. coli LPS, while iMPLA was not different from LPS for 
TNFα, IL-6, or IL-1β expression. These results indicate that pre-incubation of LPS with one of 
the two alkaline phosphatases, at the same ratio of AP:LPS results in MPLA being significantly 
less inflammatory and iMPLA being either more inflammatory than MPLA or just as toxic as 
LPS treatments alone. Future studies should focus on the specifics of enzymatic activity for the 
two AP and determine any differences in the kinematics of LPS dephosphorylating ability.  
Weaning piglets were challenged with vehicle, Salmonella LPS, or MAP-detoxified 
Salmonella LPS to determine if the in vitro results could be recapitulated in vivo. The authors 
chose to use Salmonella LPS for the immune challenge due to in vitro results showing that 
detoxified Salmonella LPS was less stimulatory than detoxified E. coli LPS. Salmonella LPS 
significantly raised circulating TNFα levels at two and four hours post-injection, while MPLA-
treated piglets were never different than controls. These results agree with Bentala et al. (2002) 
in which Balb/c mice were i.p. injected with Salmonella minnesota LPS or MPLA from S. 
minnesota. Bentala and coworkers reported that MPLA treatment was not sufficient to elevate 
circulating TNFα at one, two, three, or four hours post injection102.  Salmonella LPS also 
significantly upregulated plasma IL-6 levels at two hours post-injection, in contrast, MPLA 
treatment did not affect circulating IL-6. IL-10 is released to inhibit the production of TNFα and 
IL-16 and is associated with the disappearance of clinical signs and return to homeostasis. LPS 
treatment significantly increased circulating IL-10 above both saline and MPLA piglets. There 
was no differences between saline or MPLA-injected piglets for circulating IL-10, demonstrating 
the modulated immune response. Finally, IL-4 plasma levels were significantly different than 
LPS and control treated piglets, and LPS and MPLA treated piglets. IL-4 is an essential anti-
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inflammatory cytokine and activator of Th2 helper cells, which secrete more IL-4 in a positive 
feedback manner. The elicitation of IL-4 by LPS but not MPLA, confirms that MPLA is 
significantly less toxic to a weaning piglet and therefore requires less immune activation. 
Furthermore, IL-4 signaling activates STAT6, which mediates repression of PPARα by 
preventing PPARα recruitment to target genes. This leads to a significant reduction in the 
expression of proteins involved in the citric acid cycle, fatty acid oxidation, and oxidative 
phosphorylation103,104. This release of glucose and fatty acids is used to fuel the activated 
immune system; however, glucose and fatty acids are used for growth and development in a 
young mammal. Therefore, these results indicate the LPS-induced increase in circulating IL-4 
levels during the immune challenge could inhibit muscle accretion and bone growth by releasing 
those building blocks, but MAP-detoxified LPS would not interfere with this process. More 
research is needed to determine if exogenous MAP supplementation would interact with LPS in 
the intestinal lumen to produce MPLA, and MAP would exert a protective effect overgrowth 
arrest during weaning.  
Cytokine gene expression in the liver and spleen were examined at the end of the 4-hour 
immune challenge to confirm ELISA results. Splenic TNFα expression was significantly 
elevated in LPS injected piglets but not with MPLA. LPS also elevated IL-6, IL-1β, and IL-10 
levels in the liver and spleen. TNFα is promptly released from immune cells and is a potent 
activator of the NF-ĸB pathway, which amplifies the immune response through increasing pro-
inflammatory cytokine expression98. The inability of MPLA to elicit a change in splenic TNFα 
gene expression attests to the ability of MAP to detoxify LPS.  
Given that MPLA is derived from LPS, and in vitro results showed a significant decrease 
in TLR4 stimulation, we hypothesized that i.p. administration of MPLA would result in 
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decreased piglet sickness behavior. Behavior was examined throughout the study for activity and 
food intake, and with feed being removed 3 hours before the study to control for natural lack of 
appetite. LPS-treated piglets spent significantly less time eating and were less active than vehicle 
or MPLA-injected piglets. This is in contrast to Eimerbrink et al. (2016) that showed MPLA 
stimulation alone disrupted burrowing behavior in C57BL/6J mice, as compared to saline-treated 
mice105. This difference in results could be attributed to species differences and sickness 
behavior paradigms. The same study showed pretreatment with MPLA protected against LPS-
induced sickness behavior. Endotoxin tolerance is the reduced capacity of a cell to respond to 
LPS after initial exposure and occurs as the result of persistent TLR4 stimulation106,107. 
Contemporary literature is exploring the ability of TLR4 agonists, such as MPLA, inducing 
cross-tolerance to LPS; however, the ability of microbial AP-derived MPLA to exert these 
protective effects has yet to be examined and could be a therapeutic agent for LPS-mediated 
diseases. 
In a therapeutic context, work on the beneficial effects of exogenous MPLA and IAP 
supplementation have been wide-reaching. TLR4 activation and the subsequent pro-
inflammatory response can detrimental to healthy growth and function, although the immune 
stimulatory properties play a significant role in host protection. MPLA is currently being utilized 
as a vaccine adjuvant for its ability to stimulate the immune system, without overwhelming host 
defenses108. TLR4 stimulation with MPLA also significantly improves Alzheimer’s disease-
related pathology by increasing the ability of microglia to phagocytize Aβ plaques109. Oral 
supplementation of IAP decreases the severity of Clostridium difficile infection and protects 
against antibiotic-induced dysbiosis110. Finally, exogenous IAP has been shown to prevent high 
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fat diet-induced metabolic syndrome and reverse changes associated with metabolic 
syndrome111.  
 In this paper, we have shown that microbial-derived alkaline phosphatase detoxifies both 
Salmonella and E. coli LPS in murine macrophages and primary porcine alveolar macrophages, 
and i.p. administration of the product MPLA in weaning piglets resulted in significantly lower 
circulating pro- and anti-inflammatory cytokines, lower mRNA expression of cytokines in 
primary immune organs and is not potent enough to elicit sickness behavior. Novel findings 
indicate a bolstered ability of MAP to detoxify Gram-negative bacteria, as compared to IAP. 
Taken together, these present findings suggest microbial-derived AP, and MPLA could represent 





CHAPTER 3: DIETARY INTERVENTION WITH MICROBIAL-DERIVED ALKALINE 
PHOSPHATASE EXERTS PROTECTIVE EFFECTS AGAINST POST-WEAN SYNDROME 
IN PIGLETS  
 
3.1 Abstract 
 Piglet weaning is associated with growth plateaus, inflammation, and increased endotoxin 
load in the gastrointestinal tract (GIT). Furthermore, weaning is characterized by perturbations in 
GIT enzymatic activity and morphological changes, which drive further inflammation and 
decrease the digestive and absorptive capacity of the small intestine, as well as overwhelm the 
innate immune response.  Increased inflammation and bacterial load lead to displaced tight 
junction proteins (TJP) and inhibits the immunoprotective effects of intestinal alkaline 
phosphatase (IAP). Recent in vivo data from our lab has shown that microbial-derived alkaline 
phosphatase (MAP) is capable of detoxifying lipopolysaccharide (LPS), an endotoxin from 
Gram-negative bacteria such as E. coli. In the present study we focused on elucidating the effects 
of exogenous MAP supplementation on piglets post-wean. We found that MAP-fed piglets had a 
higher average daily gain (P=0.004) and increased villus height to crypt depth ratio in the 
duodenum, jejunum, and ileum (P<0.001). Compared to control piglets, MAP-fed piglets had 
increased gene expression of TJP ZO-1 in the jejunum (P<0.001) and ileum (P=0.05), and 
decreased gene expression of duodenal and jejunal claudin-1 (P=0.04; P=0.02). Duodenal 
(P=0.009), jejunal (P=0.006) and ileal (P=0.003) IAP gene expression was substantially 
upregulated in MAP-supplemented piglets. Finally, exogenous MAP increased alkaline 
phosphatase enzymatic activity in the digesta of the duodenum (P<0.001), jejunum (P=0.03) and 
ileum (P=0.002); and the mucosa of the duodenum (P=0.04), jejunum (P=0.002), and ileum 
55 
 
(P=0.02). Taken together, these results indicate a novel therapeutic intervention approach to 
protect piglets against weaning-induced growth plateaus, disruptions against GIT tight junction 
proteins, and inhibition of IAP and AP activity due to increased bacterial load and inflammation 
during the post-weaning period. 
 




In the modern industrial swine industry, weaning is the most challenging and stressful 
point in the pig’s life due to major nutritional, psychological, and environmental stressors. The 
post-weaning phase is often accompanied by reduced growth performance, reduced feed intake, 
and increased incidence of diarrhea and bacterial translocation1,2. The gastrointestinal tract is 
lined with a single layer of epithelial cells that form a selective barrier and act as the first line of 
defense against potentially harmful compounds and microorganisms in the intestinal lumen. 
Intestinal barrier dysfunction is characterized by increased intestinal permeability, or “leaky 
gut,” which allows harmful immunogenic agents to cross the epithelium and gain access to 
protected tissues and systemic circulation. This breach of the epithelial lining and subsequent 
translocation of luminal contents contributes to increased inflammation, malabsorption, diarrhea, 
and potential enteric disease4,19,20.  
Enterocytes are joined together by tight junctions that consist of proteins which function 
to connect the cytoskeletons of adjacent enterocytes24. Tight junctions are mainly constructed 
from the transmembrane protein complexes occludin and claudin, and the cytosolic protein 
zonula occluden. Alterations in tight junction proteins (TJP) are biomarkers of increased 
intestinal permeability. Increased translocation of enteric pathogens, including endotoxins from 
Gram-negative bacteria such as E. coli, disrupt these proteins and increase intestinal 
permeability25. Endotoxins, such as Gram-negative bacteria cell wall component 
lipopolysaccharide (LPS), spontaneously release and can cause structural changes in the small 
intestine by disrupting the structure of tight junctions and causing the internalization of TJP 
occludin, which allows pathogens to cross into systemic circulation61,64. Inflammatory mediators, 
such as the pro-inflammatory cytokine TNFα, are released from cells, such as innate lymphoid 
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cells and epithelial cells, following LPS-stimulation and increase intestinal permeability by 
disrupting expression of claudins and occludins and by altering the lipid environment of 
phospholipid membranes to displace TJP65,66. 
The epithelial lining of the small intestine is covered in villi, small finger-like 
projections, to increase surface area for digestion and absorption5. Optimal function of the small 
intestine favors long villi. Following weaning, there is a brief period of villous atrophy and crypt 
hyperplasia that leads to impaired gut absorptive capacity and decreases digestive and brush-
border enzymatic activity3,7,8.  
Alkaline phosphatases (AP) are homodimeric enzymes that catalyze the hydrolysis of 
monoesters of phosphoric acid and transphosphorylation reactions. Intestinal alkaline 
phosphatase (IAP) is a glycoprotein anchored in the apical membrane of the small intestine and 
is found in the highest levels in the duodenum, followed by the jejunum and ileum. IAP has 
several biological roles, including being a negative regulator of intestinal fat absorption, 
maintaining bicarbonate secretion and pH balance, and exerting immuno-protective effects68,69. 
The toxicity of LPS, specifically the lipid A moiety, is dependent upon its phosphorylation 
state72. A significant role of AP in vivo is to detoxify bacterial LPS that is present in the intestinal 
lumen. High levels of IAP can control LPS-induced inflammation in two ways: by 
dephosphorylating LPS and decreasing TLR4 stimulation, and by preventing NF-ĸB 
translocation to the nucleus by inhibiting the phosphorylation of two critical proteins in the 
pathway, IĸBα and RelA/p6575. The ability of IAP to dephosphorylate LPS, at physiological pH, 
and to reduce the toxic effects in vivo was first shown in 199773,74. 
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During weaning, piglets go through a fasting period as their immature digestive and 
immune systems are catching up, and it is well known that fasting dramatically decreases IAP 
activity78.  
Porcine epidermal growth factor (pEGF) is found in sow milk and contributes to 
postnatal gut mucosal growth and development, and a recent study showed that supplementing 
weaned pigs with exogenous pEGF caused an increase in gene expression and protein activity of 
digestive enzymes in the GIT, including IAP81,82. Fasting also decreases Lactobacillus 
populations, which allow for overpopulation of Gram-negative bacteria and increased LPS 
concentrations in the lumen, and the probiotic Lactobacillus casei has been shown to stimulate 
IAP activity80. IAP’s ability to reduce bacterial translocation and attune commensal microbiota 
may be an ancillary effect of pH regulation, as an alkaline microenvironment is unfavorable for 
the growth of pathogens68. 
Previous work by members of our lab showed that, like AP, microbial-derived AP (MAP) 
can detoxify Gram-negative bacterial LPS from E. coli and Salmonella and reduce the LPS-
mediated inflammatory effects in vitro and in vivo. The objectives of this study were to 
determine if exogenously supplemented microbial-derived AP would increase AP activity in the 
small intestine and exert a protective effect over post-weaning syndrome. We hypothesized that 
feeding post-weaning piglets MAP would increase duodenal, jejunal, and ileal AP activity and 
protect against the weaning-induced decrease in IAP gene expression. Furthermore, we 
quantified the effects of exogenous MAP supplementation on tight junction proteins in the small 
intestine and determined the protective effects on villus height and crypt depth.   
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3.3 Materials and Methods 
Animals and Diets 
Sixteen male PIC piglets from University of Illinois swine herd were naturally farrowed 
and weaned at 21 days of age. Piglets were kept on the premises of University of Illinois 
Imported Swine Research Farm and randomly divided into two treatment groups (n=8) 
controlling for litter of origin and body weight. Piglets were housed in four pens of four piglets 
each. All four pens were kept on standard phase 1 diet for one-week post-weaning to acclimate 
to the novel environment and piglets (Table 3.1). On postnatal day 28, two pens were switched 
to a standard phase 2 diet, and two pens were placed on a standard phase 2 diet supplemented 
with 4,000 IU/kg of MAP (Table 3.1). The experimental and control diets and fresh, clean 
drinking water were offered ad libitum throughout the experimental period. All piglets were 
maintained on control or experimental diet until postnatal day 42. Postnatal day 42, piglets were 
euthanized according to University of Illinois swine farm standard operating procedure as 
described in the AVMA Guidelines on Euthanasia, and tissues were collected for analysis. 
Representative segments from the duodenum, jejunum, and ileum were collected for histology. 
Digesta contents and mucosa were collected from duodenum, jejunum, and ileum and flash 
frozen for gene expression and AP activity. Weight of piglets was determined at post-natal day 
21, 28, 35, and 42. Group housing and ad libitum feed prevented individual feed intake data 
collection. All procedures were approved by the University of Illinois at Urbana-Champaign 














Alkaline Phosphatase Activity 
 AP activity was determined using a colorimetric assay kit (Abcam, USA, ab83369) 
according to the manufacturer’s protocol. Briefly, digesta was collected from the duodenum, 
jejunum, and ileum and suspended in an equal volume of 0.9% saline plus protease inhibitor 
cocktail (11873580001; Sigma-Aldrich) at pH 8.5, centrifuged and supernatant collected for 
assay. Mucosal scrapings were collected with a glass slide from the duodenum, jejunum, and 
ileum and homogenized with equal volume 0.9% saline plus protease inhibitor cocktail at pH 
8.5. The homogenized mucosa was centrifuged and pelleted and the supernatant collected for 
assay. AP activity was determined with respect to the release of p-nitrophenol from the p-
nitrophenylphosphate (pNP) substrate. Each reaction was initiated by the addition of pNP to 
small intestine mucosa and digesta, and the reaction was stopped sixty minutes later with the 
addition of stop solution. Optical density was measured at 405 nm to quantify the amount of p-
Table 3.1 Composition of experimental diets 
Ingredient (%) Control  MAP 
Corn 42.02  42.01 
Soybean meal 31.50  31.49 
Whey 20.00  19.99 
Fat 3.00  3.00 
Dicalcium phosphate 0.70  0.70 
Limestone 1.20  1.20 
L-lysine-HCl 0.35  0.35 
DL-methionine 0.15  0.15 
L-threonine 0.08  0.08 
Vitamin premix 0.20  0.20 
Swine trace mineral premix 0.35  0.35 
Salt-white 0.20  0.20 
Zinc oxide 0.25  0.25 
Microbial alkaline phosphatase (MAP) 0.00  0.03 
Total 100.00  100.00 
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nitrophenol produced. AP activity was determined using the below equation where B equals the 
amount of pNP in the sample well calculated from the standard curve, ΔT is the reaction time in 
minutes, V is the original sample volume in the reaction well, and D is the sample dilution 
factor: 
𝐴𝐴𝐴𝐴𝐴𝐴 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 = �
𝐵𝐵
∆𝑇𝑇 ∗ 𝑉𝑉
� ∗ 𝐷𝐷 
 
Gene Expression 
 Total RNA from duodenum, jejunum, and ileum mucosal scrapings were isolated 
using the Tri Reagent protocol (Invitrogen). Complimentary DNA was synthesized using a high-
capacity RT kit (Applied Biosystems, Grand Island, NY, USA) according to the manufacturer’s 
instructions. Quantitative real-time PCR was performed using the Applied Biosystems Taqman 
Gene Expression Assay protocol, and relative gene expression was determined from the 
fluorescent data on an ABI PRISM 7900HT- sequence detection system (PerkinElmer, Waltham, 
MA). All primers and probes for quantitative PCR were obtained from Integrated DNA 
Technologies (Coralville, IA, USA). Genes of interest were tight junction proteins claudin 1 
(NM_001244539.1), ZO-1 (XM_003480423.4), occludin (NM_001163647.2), and intestinal 
alkaline phosphatase (XM_003133729.4). Mucosal mRNA abundance was compared to 
reference gene RPL19 (Ss03375624_g1). PCR conditions included 50°C for 2 minutes, 95°C for 
10 minutes, 40 cycles of 95°C for 15 seconds, and 1 cycle at 60°C for 1 minute. Gene expression 
was determined using the 2-ΔΔCt calculation method as previously described 96. Data are 






Representative sections of the duodenum, jejunum, and ileum were removed at places 
along the whole length of the small intestine. The samples were fixed in 10% neutral buffered 
formalin for 48 hours and then embedded in paraffin wax by standard techniques. From each 
sample, five transverse sections were fixed on two slides and stained with hematoxylin and 
eosin. To reduce variability in measuring, villus height and crypt depth were measured by the 
same person who was blinded to treatment. All morphological measurements were made using 
the Nanozoomer-XL (Hamamatsu Photonics, Bridgewater, NJ). Villi height were measured by 
picking five intact, representative villi for each small intestine section across two slides per S.I. 
section. The height of each villus was measured from tip to crypt-villus junction. Crypt depth 
was measured from five crypts for each small intestine section that was associated with intact 
villi. Crypt depth was measured from the crypt-villus junction to the base.  
 
Statistics 
Data were analyzed by one-tail unpaired students T-test with Welch’s correction when 
appropriate or by Mann-Whitney U-test. Statistical significance was set at p≤0.05. Analysis was 
performed using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, CA) 
or SAS™ 9.4 software (SAS Institute, Cary, NC, USA). All data are expressed as means ± 
standard error of the mean.  




Feeding weaned piglets microbial-derived alkaline phosphatase mitigates weaning-induced 
growth plateau  
 Piglets were weaned, and both treatment groups received a standard phase 1 diet for one-
week post-weaning to normalize the gastrointestinal tract and then given a standard phase 2 diet 
for two weeks with or without MAP supplementation (Fig 3.1a).  Piglets supplemented with 
4,000 IU/kg feed MAP had a heavier body weight after 14-days of MAP supplementation than 
piglets on a standard phase 2 diet (P=0.016) (Fig 3.1b). Furthermore, piglets fed the MAP-
supplemented diet had a higher average daily gain during the second week of the experimental 
period (P=0.004). (Fig 3.1c).  
 
MAP supplementation exerts positive effects on villus height and crypt depth 
 Piglets receiving a phase 2 diet supplemented with MAP had longer villi in the duodenum 
(P=0.006) and jejunum (P=0.03) than control fed piglets (Table 3.2). There were no differences 
(P=0.XX) in ileal villus height. Furthermore, MAP fed piglets had more shallow crypt depth in 
the duodenum (P=0.002), jejunum (P=0.002), and ileum (P<0.001). Finally, villus height to crypt 
depth ratio was calculated and MAP fed piglets had an increased VH:CD ratio in the duodenum, 
jejunum, and ileum (P<0.001). Differences in VH and CD are visible in representative sections 






Piglets supplemented with MAP post-wean have increased small intestine alkaline 
phosphatase activity  
To determine if exogenous MAP supplementation could be detected in the small 
intestine, digesta and mucosa from duodenum, jejunum, and ileum were collected, and the 
amount of pNP hydrolyzed quantified.  We first investigated if MAP activity could be detected 
in the small intestine and would not be hydrolyzed by stomach acid (Fig 3.3a-c). Compared to 
control weaning piglets, piglets fed a phase 2 diet supplemented with MAP had substantially 
increased AP activity in the digesta of the duodenum (P<0.001), jejunum (P=0.03) and ileum 
(P=0.002). Furthermore, we determined an increase in mucosal AP activity in the duodenum 
(P=0.04), jejunum (P=0.002), and ileum (P=0.02) of MAP-supplemented piglets compared to 
animals fed the control diet (Fig 3.3d-f). Taken together, the above results indicate that feeding 
exogenous MAP during weaning rescues weaning-induced decreases in AP enzymatic activity in 
small intestinal mucosa and digesta. 
 
MAP-supplemented piglets are protected against weaning-induced downregulation of 
intestinal alkaline phosphatase and tight junction protein gene expression. 
 Since IAP levels are known to decrease during weaning, we sought to determine the 
effects of feeding MAP post-weaning on IAP gene expression in the small intestine (Fig 3.4a). 
Piglets fed the experimental diet were substantially protected against weaning-induced 
downregulation of IAP in the duodenum (P=0.009), jejunum (P=0.006), and ileum (P=0.003). 
Tight junction proteins in the gastrointestinal tract are disturbed during weaning and contribute 
to increased gut permeability. Therefore, we measured ZO-1, claudin-1, and occludin gene 
expression in the duodenum, jejunum, and ileum (Fig 3.4b-d). Compared to control piglets, 
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MAP-fed piglets had higher levels of ZO-1 mRNA in the jejunum (P<0.001) and ileum (P=0.05). 
MAP-supplemented piglets had a decrease in duodenal (P=0.04) and jejunal (P=0.02) claudin-1 
gene expression. There were no differences between control and MAP-supplemented piglets for 
occludin gene expression in the small intestine. Taken together, these results indicate that 
supplementing piglets with MAP during the post-weaning phase protects against weaning-


















(n = 8 ) The results are presented as mean ± SEM. 
Table 3.2 Effects of MAP supplementation on villus height (VH), crypt depth 
(CD), and villus height: crypt depth ratio (VH:CD) of piglets three weeks post-
wean 
Effects 
Diet   
P-value 
Control  MAP Supplemented  
          
VH (µm)       
Duodenum 451 ± 20.3  560 ± 31.4  0.006 
Jejunum 452 ± 45.3  553 ± 20.1  0.030 
Ileum 340 ± 25.4  383 ± 22.8  0.115 
CD (µm)       
Duodenum 206 ± 8.3  161 ± 10.3  0.002 
Jejunum 199 ± 11.3  148 ± 8.4  0.002 
Ileum 175 ± 2.5  112 ± 5.1  <0.001 
VH:CD ratio       
Duodenum 2.22 ± 0.13  3.51 ± 0.09  <0.001 
Jejunum 2.29 ± 0.19  3.59 ± 0.07  <0.001 
Ileum 1.94 ± 0.14  3.44 ± 0.20  <0.001 
          















3.5 Discussion and Future Directions 
Previous work in our lab has shown that MAP can detoxify LPS from members of Gram-
negative bacteria and reduce the inflammatory effects in vitro and in vivo. In the present study, 
we found that supplementing post-weaning pigs with MAP protects against weaning-induced 
growth depression, villous atrophy and crypt hyperplasia, decreased IAP activity and gene 
expression, and disruption of tight junction proteins. 
At weaning, piglets are moved from a highly digestible liquid diet to a less palatable dry 
diet, and as a consequence, feed intake is reduced, and the piglet has reduced nutrient absorption 
and utilization leading to reduced growth performance. It is essential to get pigs growing as soon 
as possible after weaning, and Tokach et al. (1992)  reported that weight gain in the first few 
weeks after weaning impacts the total days to market112. We found that weaned piglets fed a 
standard phase 2 diet supplemented with 4,000 IU/kg body weight MAP gained significantly 
more body weight during the second week of study compared to piglets fed a standard control 
phase 2 diet. Furthermore, during the second week on the experimental diet, piglets 
supplemented with MAP had a significantly higher average daily gain. The extent to which this 
increase in body weight and ADG continue throughout the feeder period or the effects of 
supplementing MAP immediately post-weaning requires more research. Taken together, these 
results indicate a novel therapeutic approach to decreasing growth depression in weaning piglets.  
Intestinal morphology, including villus height, crypt depth, and VH:CD of the duodenum, 
jejunum, and ileum can be indicative of overall piglet gut health. Post-weaning, villus height is 
reduced, and crypt depth increases. Longer villus height has been associated with active cell 
mitosis and greater nutrient absorption, and the villus height/crypt depth ratio correlates with 
epithelial turnover113,114. Villus crypts provide new villi, and deeper crypts increase tissue 
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turnover to allow the renewal of villi in response to normal sloughing, inflammation from 
pathogens, or high demand in a growing animal. In the present study, dietary supplementation of 
MAP reported an increase in villus height in the duodenum and jejunum and a decrease in crypt 
depth in the duodenum, jejunum, and ileum. Furthermore, there was a significant increase in the 
villus height to crypt depth ratio for all segments of the small intestine. To our knowledge, this is 
the first study of its kind to evaluate the effects of exogenous AP supplementation on gut 
morphology of post-weaning piglets. Reduced intestinal inflammation from MAP detoxifying 
bacterial components in the lumen and increased weight gain from enhanced utilization of 
enteral nutrients may be responsible for the optimal villus height and crypt depth that is seen in 
MAP-supplemented piglets.  
Post-weaning syndrome is also associated with increased mucosal attachment of 
pathogenic Escherichia coli and other Gram-negative bacteria that potentiate the syndrome due 
to the piglet’s immature immune system. Endotoxins, such as Gram-negative bacteria cell wall 
component lipopolysaccharide (LPS), spontaneously release and can cause structural changes in 
the small intestine by disrupting the structure of tight junctions allowing pathogens to cross into 
systemic circulation61,64. Under homeostatic conditions, IAP suppresses LPS-mediated 
inflammatory responses through modulating commensal bacteria and gut pH, detoxifying LPS, 
protecting gut barrier function, and balancing fluid and electrolyte secretion. It is well known 
that IAP expression is decreased in weaning piglets and that IAP expression is dependent upon 
enteral nutrition75,115. Therefore, we sought to determine the effects of exogenous AP 
supplementation on IAP activity in weaning piglets.  
Compared to control phase 2 diet fed piglets, MAP-supplemented piglets had 
significantly higher AP activity in the digesta and mucosa of the duodenum, jejunum, and ileum. 
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Furthermore, MAP-supplemented piglets had significantly higher IAP gene expression in the 
duodenum, jejunum, and ileum. Weaning-induced inflammation is marked by upregulation of 
pro-inflammatory mediators such as TNFα and IL-6, which have been shown to inhibit IAP 
expression116,117. Since weaning is known to increase endotoxin load and LPS is known to 
upregulate TNFα and IL-6, and one of IAP’s biological roles is to mitigate the inflammatory 
effects of LPS and protect against bacterial translocation; it is possible the increase in IAP 
activity and expression is due to exogenous MAP detoxifying LPS in the lumen and protecting 
against inflammatory mediators. AP also create an alkaline microenvironment that is unfavorable 
for pathogen attachment, and exogenous MAP could potentiate this alkaline environment for 
optimal commensal bacterial growth which would reduce the concentration of unfavorable 
pathogens118,119. A commensal bacterial environment would protect against inflammation and 
downregulation of IAP activity and expression. 
 IAP is a marker for enterocyte differentiation, and weaning is associated with decreased 
feed intake, which decreases enterocyte differentiation. Since MAP-supplemented piglets had 
significantly higher average daily gain, the increase in IAP gene expression could be in part due 
to increased feed intake. Increased feed intake would increase rapamycin-dependent signaling 
pathways, which would stimulate the global synthesis of intracellular proteins, including IAP. 
Therefore, MAP-supplementation could increase IAP expression and/or activity in the digesta 
and mucosa through multiple mechanisms and exerts a protective role against weaning-induced 
decreases in IAP activity.  
In the weaned piglet, downregulation of the IAP gene is associated with poor intestinal 
integrity120. Intestinal permeability has long been considered to be a measure of intestinal barrier 
function. The intestinal barrier is regulated by a complex system of transmembrane and cytosolic 
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proteins called tight junction proteins. The most critical components of a tight junction are 
transmembrane proteins occludin and the claudin family, specifically claudin-1, and the linker 
protein ZO-1. Occludin is an integral membrane protein having functional roles in maintaining 
the integrity of the tight junction121. Claudin-1 has diverse functions depending on cell type and 
host but is localized to ZO-1 expression. ZO-1 is a vital intracellular tight junction protein that is 
essential for tight junction assembly and link the cell cytoskeleton to transmembrane tight 
junction proteins occludin and claudins122. Inflammatory mediators, such as pro-inflammatory 
cytokine TNFα, are released following LPS-stimulation and increase intestinal permeability by 
disrupting expression of claudins and occludins and by altering the lipid environment of 
phospholipid membranes to displace tight junction proteins65,66 Furthermore, TNFα is thought to 
mediate effects on tight junctions by downregulating ZO-1 stability and concentration at the 
junctional surface123. In human and mice, exogenous IAP has been shown to prevent the 
development of colitis, a disease marked by poor intestinal permeability111,124,125. Furthermore, 
IAP treatment has been shown to prevent increased intestinal permeability in a mouse starvation 
model126. 
 In the present study, we found that MAP supplementation significantly upregulated gene 
expression of tight junction protein ZO-1 in the jejunum and ileum, decreased claudin-1 in the 
duodenum and jejunum, and exerted no effect on occludin gene expression. Our results agree 
with Liu et al., (2016) which showed that IAP treatment preserved localization of ZO-1 and 
occludin proteins during inflammation. The same study also showed that IAP gene deletion in 
mouse embryonic fibroblasts resulted in lower levels of ZO-1, ZO-2, and occludin compared to 
wild-type controls127. Zinc is an important cofactor for optimal AP activity and Zhang et al., 
(2019) showed that zinc supplementation alone was sufficient to enhance ZO-1 expression in 
75 
 
weaning piglets, and zinc-supplemented piglets had a significantly higher ADG128. Taken 
together, these results argue that AP exerts a protective effect on ZO-1 disruption during 
weaning-induced anorexia and inflammation. Studies have shown a strong correlation between a 
decrease in ZO-1 and occludin and an increase in intestinal permeability and a decrease in trans-
epithelial resistance129. Furthermore, recent literature has shown that tight junction protein 
claudin-1 is increased during intestinal inflammation130. In the present study, we found a 
decrease in claudin-1 in MAP fed piglets, and this may be due to decreased intestinal 
inflammation as compared to control fed weaned piglets. We saw no change in occludin gene 
expression, which is in contrast to Liu et al., (2016) which showed IAP preserved occludin 
expression in mouse models where colitis decreased the expression. These differences could be 
due to differences in species and the pathology of weaning versus colitis.  
Environmental and physiological stressors during weaning lead to a decrease in feed 
intake and increased intestinal inflammation, which causes changes to intestinal permeability and 
enzymatic activity. Together, these consequences potentiate each other and drive inflammation 
and bacterial translocation, which can lead to growth depression and a high mortality rate during 
piglet weaning. Exogenous MAP supplemented during the post-weaning phase protected piglets 
by detoxifying LPS in the gut lumen and creating an alkaline environment unfavorable for 
pathogen attachment and growth. Decreased inflammation during weaning leads to increased 
nutrient absorption, which protects against further GIT morphological changes and anorexia-
induced decreases in tight junction proteins and endogenous IAP. Furthermore, lower 
concentrations of endotoxins, and subsequently inflammatory mediators, due to exogenous MAP 
detoxifying LPS prevent further decreases in endogenous IAP and ZO-1, and increases in 
claudin-1. Maintaining healthy levels of TJP and IAP allows for an increased growth rate of the 
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weaned piglet, a more robust immune system, and a protected GIT against opportunistic 
pathogens. Taken together, the results of these studies indicate a novel therapeutic approach to 
overcoming post-wean growth plateaus, enhancing small intestinal VH:CD ratios, protecting TJP 
expression in the small intestine during inflammation, and maintaining high levels of IAP to 
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